Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30433615 | 1.00 | GPR35 (0.31) | GPR35 | |
| SCHEMBL25167501 | 0.78 | PDPK1 (0.36) | — | |
| SCHEMBL30401622 | 0.76 | GPR35 (0.31) | GPR35 | |
| SCHEMBL25169268 | 0.76 | GPR35 (0.31) | GPR35 | |
| SCHEMBL25175097 | 0.74 | PDE4B (0.32) | — | |
| SCHEMBL14830510 | 0.68 | EPHB4 (0.32) | GPR35 | |
| SCHEMBL22346635 | 0.68 | GPR35 (0.31) | GPR35 | |
| SCHEMBL25168095 | 0.67 | — | — | |
| SCHEMBL31373103 | 0.67 | PDPK1 (0.36) | GPR35 | |
| SCHEMBL20443615 | 0.63 | ALDH1A1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340564-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250101034-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2025-03-27 | — | — | US | disclosed |
| EP-4426704-A1 | CONDENSED PYRIDAZINE AMINE DERIVATIVES TREATING SCA3 | Skyhawk Therapeutics, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| WO-2023081857-A1 | CONDENSED PYRIDAZINE AMINE DERIVATIVES TREATING SCA3 | SKYHAWK THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081857-A1 | CONDENSED PYRIDAZINE AMINE DERIVATIVES TREATING SCA3 | SKYHAWK THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081858-A1 | CONDENSED-PYRAZINE AMINE DERIVATIVES FOR TREATING SCA3 | SKYHAWK THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101034-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | RBM17, SNRPE, SNRPA1 | GPR35 4208/4885 |
| US-20250340564-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | RBM17, SNRPE, SNRPA1 | GPR35 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.